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Abstract Eukaryotic initiation factor 4E (eIF4E) binds the 5P-
cap of eukaryotic mRNAs and overexpression of eIF4E in
epithelial cell cancers correlates with the metastases/tissue
invasion phenotype. Photolabeling of eIF4E with [Q-32P]8-
azidoguanosine 5P-triphosphate (8-N3GTP) demonstrated cross-
linking at Lys-119 in the S4^H2 loop which is distant from the
m7GTP binding site [Marcotrigiano et al. (1997) Cell 89, 951^
961; Friedland et al. (1997) Protein Sci. 6, 125^131]. Modeling
studies indicate that 8-N3GTP cross-linked with Lys-119 because
it binds a site that is occupied by the second nucleotide of a bound
mRNA. Mutagenesis of the S4^H2 loop produced proteins with a
5^10-fold higher affinity for m7GTP than wild-type eIF4E. These
mutants of eIF4E may have uses in selectively purifying mRNAs
with intact 5P-ends or in determining how the promyelocytic
leukemia protein decreases the affinity of eIF4E for mRNA
caps. ß 2002 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
Key words: RNA binding protein; Eukaryotic initiation
factor 4E; mRNA cap; m7GTP; Translation
1. Introduction
Regulation of gene expression at the level of translation
occurs in many biological processes including cell growth
and di¡erentiation, embryonic development, and viral infec-
tion. Evidence is accumulating that perturbations in mRNA
translational elements play a major role in the biology of
some cancers [3^7]. In addition, at least one small molecule
anti-cancer agent is believed to exert its e¡ect by inhibiting
initiation of mRNA translation [8]. A critical protein mediat-
ing early events in initiation of translation is the eukaryotic
initiation factor 4E (eIF4E). eIF4E serves as an intermediary
between the 5P-cap (m7G(5P)ppp(5P)N), several other initiation
factors plus the poly(A) binding protein (PAB), and the 3P-
poly(A) tail of eukaryotic mRNA [9,10]. It has a binding site
for m7GDP on one side and a binding site for eukaryotic
initiation factor 4G (eIF4G) (or PHAS-I) on the other side
of its central L-sheet [1,11,12]. eIF4E is part of the eIF4F
complex that includes eIF4G, which binds ribosomes and
PAB, and eIF4A, which is an ATP-dependent RNA helicase
[13]. The binding of eIF4F and eIF4B to the mRNA cap
appears to be a key step in the ATP-dependent unwinding
of mRNA structure and ribosome binding which are rate
limiting events for the translational initiation of many eukary-
otic mRNAs [14].
eIF4E and assembly of the eIF4F complex are targets of
regulation during the stimulation of cell growth and di¡er-
entiation [15^17]. In addition, overexpression or microinjec-
tion of eIF4E causes malignant transformation in NIH 3T3
cells and aberrant growth in HeLa cells [18,19]. Elevated levels
of eIF4E mRNA and protein are found in a variety of epi-
thelial cell cancers [3,5]. The binding of eIF4E to eIF4G is
regulated by interactions with translational repressor proteins
which sequester eIF4E for release under selected physiological
conditions [20,21]. On the other hand, eIF4E- and eIF4E-as-
sociated proteins are targeted during growth inhibitory events.
For example, during apoptosis at least one eIF4E-associated
protein is targeted for proteolytic destruction [22]. In addition,
the promyelocytic leukemia protein (PML) which inhibits cell
transformation and growth has recently been shown to bind
eIF4E and decrease the a⁄nity for mRNA caps [23,24].
The structure of a cocrystal of mammalian eIF4E bound to
m7GDP and the structure of yeast eIF4E bound to m7GDP in
solution have been solved [1,11,12]. Both studies describe a
cap binding slot for eIF4E in which the m7G moiety is sand-
wiched between the side chains of two tryptophans, Trp-56/
Trp-102 in mammalian and Trp-58/Trp-104 in yeast eIF4E.
Mutagenesis studies of the m7GDP binding site of eIF4E
support the hypothesized Z^Z stacking that occurs between
the m7G moiety and the two tryptophan residues [25]. In
addition, several residues interact with m7G by hydrogen
bonding. These include Trp-166 in mammalian and yeast, as
well as Glu-103 in mammalian, and Glu-105 in yeast eIF4E
which form hydrogen bonds with m7G [1,11].
The results of speci¢c photoa⁄nity labeling of recombinant
mammalian eIF4E with [Q-32P]8-azidoguanosine 5P-triphos-
phate (8-N3GTP) suggested that residues near Lys-119, the
site of photoinsertion, interacted with this nucleotide probe
[2]. We report a molecular model built with the coordinates
of eIF4E/m7GDP cocrystal structure and its use to identify
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possible binding sites for the [Q-32P]8-N3GTP probe on the
surface of eIF4E near the S4^H2 (N118^Q120) loop. The
site of cross-linking of the nucleotide probe, the S4^H2
loop, was analyzed by mutagenizing residues Asn-118 through
Gln-121 to alanine and determining the e¡ect on 4E functions.
2. Materials and methods
2.1. Modeling of the capped mRNA binding site of eIF4E
The eIF4E structure was studied to determine the possible binding
site of [Q-32P]8-N3GTP ([1,2], PDB ID# 1EJ1, 1EJ4, 1EJH). The pro-
gram DOCK was run on the apo-protein structure (eIF4E without
m7GDP present) to locate potential mRNA binding sites on the pro-
tein surface [25]. First, cavities were located on the protein surface by
probing with a sphere equivalent to H2O (1.4 Aî ). A cavity is de¢ned
by a cluster of spheres which are in contact and are complementary to
a pocket in the molecular surface of the protein. More than 20 cavities
were located on the surface of eIF4E. Three interconnected cavities
localized near the site of m7GDP in the cocrystal structure were
searched for nucleotide binding sites. When searched with m7GDP
as the ligand, DOCK located a m7GDP binding site within 1.5 Aî
of the m7GDP bound in the cocrystal structure. Next GMP was
used as the ligand to search for other possible mRNA binding sites
because it is a single repeating unit of RNA. An atomic match of
GMP to a subset of spheres within a cavity de¢ned a potential nu-
cleotide binding site. All potential GMP binding sites were located
and sorted to identify those which positioned the ribose and phos-
phate of the base in an appropriate orientation to form growing RNA
chains of three nucleotides from a m7GDP moiety which was ¢xed as
in the cocrystal structure [1]. Two initial mRNA conformations
formed using this approach were submitted as ligands in £exible dock-
ing runs onto the apo-eIF4E structure using SYBYL FlexiDock [26].
The m7GDP cap was held ¢xed within the determined binding site,
the protein molecule was held ¢xed, and the remainder of the RNA
tail was allowed to £ex and rotate. These studies formed the basis for
the hypothesized location of an mRNA bound to eIF4E.
2.2. Mutagenesis of eIF4E
Wild-type eIF4Ehuman in a pET-3d vector was used as a template
for QuikChange1 PCR-based site-directed mutagenesis (Stratagene)
[25,27]. Mutagenesis primer oligonucleotides were designed to intro-
duce alanine substitutions at residues N118, K119, Q120, and Q121,
and used according to the instructions provided by the manufacturer.
All plasmids were sequenced (both strands of the eIF4E coding re-
gion) to con¢rm mutagenesis. The nomenclature of mutants indicates
the substituted amino acid, its position, and the replacing residue (e.g.
lysine at position 119 replaced by alanine is designated K119A).
2.3. Expression and puri¢cation of eIF4E mutants and PHAS-I
Escherichia coli BL21(DE3) expressing wild-type or mutants of
eIF4Ehuman were grown at 37‡C in M9ZB media containing ampicil-
lin. Cells were induced at an OD600 of 0.6 with 0.4 mM IPTG and
incubated for an additional 3 h. Wild-type and mutant proteins were
puri¢ed from these cultures as previously described [27]. PHAS-I was
expressed and puri¢ed as described elsewhere [28]. The PHAS-I ex-
pression vector and rabbit anti-PHAS-I antibodies were kindly pro-
vided by Dr. J.C. Lawrence [28].
2.4. Circular dichroism measurements
Circular dichroism spectra of FPLC-puri¢ed eIF4E proteins were
measured on a Jasco-J710 spectropolarimeter [29,30]. Spectra were
obtained in a 0.1 M phosphate bu¡er at pH 7.6. All measurements
were performed using a 0.5 mm pathlength quartz cell at 25‡C. Each
sample was scanned 10 times and high frequency noise reduction was
applied. Data were recorded at 0.5 mm intervals with a time constant
of 1.0 s and a 1.0 nm constant spectral bandwidth.
2.5. Fluorescence measurements of the Kd of eIF4E for m7GTP
Fluorescence titration experiments were performed to determine the
Kd of m7GTP binding to wild-type and mutant eIF4E. The bu¡er
used for all £uorescence measurements was 20 mM HEPES-KOH
(pH 7.6) and 1 mM dithiothreitol (DTT). Measurements were per-
formed at 25‡C on a SPEX Fluorolog-T2 spectro£uorometer
equipped with a high intensity (450 W) xenon arc lamp. An excitation
wavelength of 289 nm was used to monitor the tryptophan £uores-
cence emission of the proteins. Excitation and emission slit widths of
1.5 and 2.0 mm, respectively, were used and a 1.0 cm sample cell path
length was employed. The steady state data were collected and ana-
lyzed as described previously [29,31].
3. Results and discussion
3.1. Modeling studies of 8-N3GTP binding to eIF4E
Previous studies have shown that an 8-N3GTP photoprobe
speci¢cally bound to mammalian eIF4E and that the site of
cross-linking was Lys-119 [2]. Modeling studies were done
with the coordinates of the eIF4E/m7GDP cocrystal to iden-
tify the most likely surface cavity that bound the 8-N3GTP
probe. They demonstrated that it was highly improbable that
the photoprobe bound to the m7GDP binding site in the coc-
rystal structure [1]. In the eIF4E/m7GDP cocrystal structure
the m7GDP binding site covers the edge of the central L-sheet
(strands 1, 3, and 5) [1]. Lys-119 is at the end of strand 4
which is two strands away from the m7GDP binding site at a
distance of approximately 19^20 Aî . The side chain of Lys-119
could not extend this distance in the model to interact with 8-
N3GTP in the m7GDP binding site (between Trp-56 and Trp-
102), and since Lys-119 is one residue o¡ the end of a L-strand
in the center of the sheet, the backbone surrounding position
119 could not extend to allow this interaction. Moreover,
other lysine residues that were on £exible loop structures
line the m7GDP binding site (Lys-49, Lys-52, and Lys-54 in
the 1^2 loop and Lys-106 in the 3^4 loop) and were more
likely candidates to cross-link with 8-N3GTP bound in the
m7GDP binding site [1]. Based on the modeling studies we
conclude that 8-N3GTP did not bind eIF4E in the m7GDP
site formed by the S1^S2 and S3^S4 loops.
If the 8-N3GTP photoprobe did not bind in the m7GDP
binding site then what site on eIF4E would speci¢cally bind
this nucleotide? Modeling suggests that in order to interact
with Lys-119, the 8-N3GTP probe bound to sites that we
hypothesize bind the second and third nucleotides of a bound
mRNA (Fig. 1B). GMP was used as the ligand to probe the
apo-protein structure of eIF4E with the program DOCK (see
C
Fig. 1. Model of GMP binding sites and m7GpppGGG bound to eIF4E. In both A and B the structure of wild-type eIF4E is displayed as a
ribbon. The L-strands are colored yellow and labeled as previously de¢ned [1]. The S4^H2 loop (extending from strand 4; residues 118^121) is
colored red. The positions of side chains of Lys-159 and Ser-209 are labeled in white. Lys-119 was modeled, labeled and displayed (capped
sticks, represented by atom color with carbons being green). A: A re¢ned set of binding sites for GMP as identi¢ed by DOCK (see Section 2).
The m7Gpp present in the eIF4E/m7GDP cocrystal structure is shown in space ¢ll. Only GMP molecules which orient the ribose and phos-
phate in the 5P to 3P direction toward the m7G cap are shown. Note that two di¡erent potential binding sites for the fourth nucleotide are
shown (lower left of the panel). B: The preferred mRNA position, as determined by modeling, is shown. The m7Gpp present in the eIF4E/
m7GDP cocrystal structure is shown in space ¢ll. The second, third, and fourth nucleotides of the modeled mRNA (m7GpppGGG) are shown
in magenta. The location of this modeled mRNA binding site is consistent with the proposed path of a capped mRNA [1], and the solution
structure of yeast eIF4E with bound m7GpppA [11]. The second nucleotide binds between Ser-209 and Lys-159, while the third and fourth nu-
cleotides pack along the edge of the cavity demarcated by Lys-159 and Lys-119.
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Section 2) and the binding sites were clustered within the
predicted path of an mRNA [1] (Fig. 1A). The bound GMP
molecules were then linked to form RNA chains
(m7GpppGGG) and minimized using FlexiDock. The pre-
dicted mRNA conformations packed in one of two binding
channels. The 5P-m7Gpp moiety and second nucleotide of
each RNA were bound in identical positions. The most fa-
vored site packed nucleotides 3 and 4 along the edge of the
cavity that is demarcated by Lys-119 and Lys-159 (Fig. 1B).
Regarding the second, third, and fourth nucleotides of the
modeled bound mRNA, the phosphate-ribose backbone and
not the bases interacted with the L-sheet of eIF4E. This mode
of binding has been observed in the cocrystal structure of VP-
39, a vaccinia virus protein that has cap-dependent 2P-O-
methyltransferase activity, with an m7G capped oligoribonu-
cleotide which permits the protein to bind RNA in a se-
quence-non-speci¢c manner [32,33]. The orientation of a
bound RNA in VP-39 and that predicted for eIF4E is di¡er-
ent from the RNA recognition motif described for RNPs that
speci¢cally bind U series RNAs [34,35]. RNPs contain sol-
vent-exposed aromatic residues on the interior L-sheet, which
stack with bases of the bound RNA in a manner that is not
base speci¢c. Such aromatic residues are not seen in the
L-sheet region forming the RNA binding site of eIF4E. In-
stead, positively charged residues (Lys, Arg) are present on
this surface, suggesting that it interacts with the phosphate
backbone of a bound RNA.
Using the modeled mRNA and allowing £exibility of the
C1^N9 bond of guanine bases and the chi1 and chi2 bonds of
Lys-119, the hydrogen on C8 of the 5P-m7G cap, of G2, and
of G3 was 20 Aî , 5 Aî , and 5 Aî away from the epsilon nitrogen
of Lys-119, respectively. This suggests that Lys-119 could not
cross-link with 8-N3GTP bound in the m7GDP cap site with-
out extensive rearrangements of the protein structure, yet
could readily cross-link with a N3GDP bound in the second
(or third) nucleotide binding site of the model with only slight
shifts in the S4^H2 loop and the S5^6 loop (Fig. 1B). Such
structural shifts were implied in the di¡erences seen in the
crystal structure of the S5^6 loop observed in the two di¡erent
asymmetric units solved [1].
The location of the modeled mRNA binding site is consis-
tent with the path of a capped mRNA bound to mammalian
eIF4E and the solution structure of yeast eIF4E with
m7GpppA (Fig. 1B) [1,11]. The capped mRNA extends
from Trp-56/Trp-102 (Trp-58/Trp-104 in yeast) and travels
through the concave surface of the L-sheet. The fact that
m7GTP was able to speci¢cally compete with photocross-link-
ing of the 8-N3GTP probe is most likely due to competition at
the level of the 3P-phosphates rather than competition between
the purine ring moieties [2]. Because of the 5P^5P linkage of the
mRNA cap, the phosphates of each NTP would be facing the
Fig. 2. Puri¢cation of eIF4E mutants. Expression and puri¢cation
of all mutants of eIF4E was performed as described in Section 2.
The recombinant proteins recovered from the ¢nal FPLC puri¢ca-
tion step were analyzed by 12% SDS^PAGE. A Coomassie blue-
stained gel with 30 Wg of each eIF4E mutant is shown.
Fig. 3. Measurements of the fraction of protein bound as a function of m7GTP concentrations were performed for wild-type eIF4E and
K119A. All measurements were done in 20 mM HEPES-KOH (pH 7.6) and 1 mM DTT, at 23‡C and at a protein concentration of 1 WM. An
excitation wavelength of 289 nm was used to monitor the £uorescence intensity at 330 nm. The symbols represent (b) wild-type and (a)
K119A eIF4E.
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phosphates of 8-N3GTP and would compete for the same
binding site (Fig. 1B). Thus as the experiments showed, the
photolabeling of 8-N3GTP was most e¡ectively inhibited by
capped mRNA (95%), m7GTP (84%), GTP (79%), and GDP
(74%) while photolabeling was inhibited only slightly by GMP
(27%) [2].
3.2. Expression and puri¢cation of eIF4E mutants
To further study the site identi¢ed by photoa⁄nity labeling,
we mutagenized the S4^H2 loop. Four eIF4E mutants were
produced with residues N118, K119, Q120, or Q121 mutated
to alanine. Wild-type and mutants of eIF4E were expressed in
E. coli and milligram quantities of proteins were puri¢ed (see
Section 2). Analysis of the puri¢ed mutants of eIF4E by SDS^
PAGE demonstrated greater than 90% purity (Fig. 2). The
yields for both wild-type and mutant eIF4E were between 1
and 2 mg of puri¢ed protein per liter of E. coli culture. Char-
acterization of the eIF4E mutants indicated that mutagenesis
did not disrupt several functions. Mutant proteins with resi-
dues 118^121 changed to alanine were able to bind m7GTP
Sepharose and had circular dichroism spectra that were sim-
ilar to wild-type eIF4E (data not shown). In addition, their
ability to bind the translational repressor protein PHAS-I was
not altered as determined by co-immunoprecipitating the two
proteins with anti-eIF4E serum (not shown).
3.3. A⁄nity of eIF4E mutants for m7GTP
The preparation of relatively large quantities of recombi-
nant eIF4E mutants permitted their Kd of binding to the
mRNA cap structure to be directly determined. Quantitation
was performed by measuring the £uorescence quenching of
intrinsic tryptophan residues in eIF4E upon m7GTP binding
at 25‡C. The Kd value of recombinant wild-type eIF4E for
m7GTP was 1.2 WM and is similar to that reported for the
native protein [29,31]. While Q121A had a Kd for m7GTP that
was similar to wild-type eIF4E (Kd of 1.1 and 1.2 WM, respec-
tively), the N118A, K119A, and Q120A mutants all had sig-
ni¢cantly higher binding a⁄nities with a Kd of 6 0.30 WM for
m7GTP. Substituting residues in strand 4 of eIF4E with ala-
nine produced no mutants with similar increases in their af-
¢nity for m7GTP (not shown). The quenching curves for wild-
type eIF4E and K119A are shown in Fig. 3. Furthermore, the
N118A, K119A, and Q120A mutants of eIF4E did not show
an ionic strength dependence for m7GTP binding as is the
case for wild-type eIF4E [29].
The interaction between eIF4E and mRNA caps is an es-
sential and regulated step of gene expression. We provide
evidence that speci¢c mutations that are distant to the m7GTP
binding site of eIF4E can increase the a⁄nity of m7GTP bind-
ing. The N118A, K119A, and Q120A mutants of eIF4E pro-
vide novel examples of isoforms of eIF4E which have an
a⁄nity for m7GTP that is up to one order of magnitude high-
er than wild-type eIF4E. All of these mutations are located in
the S4^H2 loop. One possible explanation for the observed
increased a⁄nity for m7GTP would be minor modi¢cations in
the position or orientation of the tryptophan residues, located
in the S1^S2 (W56) and S3^S4 (W102) loops, which Z^Z stack
with the m7G moiety of mRNA [1,25]. It will be interesting to
eventually determine if the mechanism(s) involved share sim-
ilarities with or are di¡erent than those explaining the de-
creased a⁄nity of mRNA cap binding that occurs when
PML binds eIF4E [23,24]. Current e¡orts are being aimed
at determining if the high a⁄nity mutants of eIF4E may
have practical use in improving methods of isolating mRNA
with intact 5P-ends [36]. A better understanding of the reason
for the increased a⁄nity of these mutants for m7GTP may
permit eIF4E to be further engineered for speci¢c purposes.
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